GLP-1 Receptor Agonists in Type 2 Diabetes: Updates and Insights for Pharmacists (Part 1 of a 2-Part Monograph Series)
Tracking # 20-1314951
Free
Course overview
The goal of this educational series is to provide pharmacists with the most up-to-date knowledge of the evolving evidence and guidelines promoting use of GLP-1 RA therapy, including current guideline recommendations to improve cardiovascular-kidney-metabolic outcomes, efficacy and safety considerations with currently available GLP-1 RAs and their effects on glycemia and weight, dosing, and administration, and patient-centered considerations for use of GLP-1 RAs to improve quality of life and outcomes.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
Dr. Neumiller has disclosed that he has served as a consultant for Proteomics International.
Dr. Trujillo has no relevant affiliations or financial relationships with a commercial interest to disclose.
Dr. Whitley has no relevant affiliations or financial relationships with a commercial interest to disclose.
The clinical reviewer, Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES has disclosed that she has received fees for consulting services from Novo Nordisk, Inc.
Susanne Batesko, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
All relevant financial relationships have been mitigated.